Abbott India Ltd NSE  /  BSE

Pharmaceuticals, Mid Cap

18 Nov 2019 | 04:01 PM

443.80 (3.59%)

Independent Research


We bring you Independent research views from famous names like Reuters and theScreeners to help improve your investing results and create wealth

Star Rating

Initiated on 01-01-70

Target Price

Performance parameters

  • Earnings Revision Trend

    Analysts negative since 20-Aug-2019

    Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 20-Aug-2019 at a price of 8986.05.

  • Valuation Rating

    Moderately overvalued

    Based on its growth potential and our own criteria, at its current price the stock is moderately overvalued.

  • MT Tech Trend

    Trend neutral but previously positive (since 21-May-2019)

    The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this (since 21-May-2019), the stock traded above its moving average. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 8515.504.

  • 4W REL Performance

    vs. SENSEX30

    The four week relative overperformance versus SENSEX30 is 5.240.

Risk parameters

  • Risk Zone


    The stock has been on the moderate-sensitivity level since 16-Apr-2019.

  • Bear Market

    Average sensitivity to market corrections

    On average, the stock is likely to decline with the index.

  • Bad News

    Slight market sanction in case of specific pressure

    When the stock's pressure is specific, the market sanction on average is 194%.

  • Beta

    79 Low sensitivity to SENSEX30

    For 1% of index variation, the stock varies on average by 79%.

  • Correlation

    0.42 Fair correlation to SENSEX30

    0.4239% of stock movements are explained by index variations.

  • Value at Risk

    Rs.1241.05 The medium term value at risk is estimated at 1241.05 or 0.14118%

    The value at risk is estimated at 1241.05. The risk is therefore 0.14118%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.

Other parameters

  • LT Growth

    23.24 Current year to 2021 annualized estimate

    The annualized growth estimate is for the current year to 2021.

  • P/E Ratio

    30.73 Estimated PE for 2021

    The estimated PE is for the year 2021.

  • G/PE Ratio

    0.78 15.364% premium to expected growth

    A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential: 15.364% premium.

  • Dividend Yield

    0.73% Dividend is largely covered by profits

    The twelve month estimated dividend yield represents 22.378% of earnings forecasts.

  • Global Evaluation


    The stock is classified in the neutral zone since 16-Apr-2019.